Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
Appendix
Innovation: Clinical trials
Respiratory & Allergy
Oncology: Solid Tumors
icenticaftor - CFTR potentiator
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04072887 (CQBW251B2201)
Chronic obstructive pulmonary disease (COPD)
Phase 2
956
Trough FEV1 (Forced Expiratory Volume in 1 second) change from baseline after
12 weeks of treatment
QBW251 450 mg
QBW251 300 mg
QBW251 150 mg
QBW251 75 mg
QBW251 25 mg
Placebo
COPD patients on background triple inhaled therapy (LABA / LAMA / ICS)
Target Patients
Read-out Milestone(s)
Publication
2022
86 Investor Relations | Q1 2022 Results
Primary publications planned for 2022
References
Abbreviations
Hematology
Biosimilars
Global Health
1 NOVARTIS | Reimagining MedicineView entire presentation